A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.

Details

Ressource 1Download: 35121086_BIB_8A000CE08497.pdf (809.18 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_8A000CE08497
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.
Journal
Journal of thoracic oncology
Author(s)
Whisenant J.G., Baena J., Cortellini A., Huang L.C., Lo Russo G., Porcu L., Wong S.K., Bestvina C.M., Hellmann M.D., Roca E., Rizvi H., Monnet I., Boudjemaa A., Rogado J., Pasello G., Leighl N.B., Arrieta O., Aujayeb A., Batra U., Azzam A.Y., Unk M., Azab M.A., Zhumagaliyeva A.N., Gomez-Martin C., Blaquier J.B., Geraedts E., Mountzios G., Serrano-Montero G., Reinmuth N., Coate L., Marmarelis M., Presley C.J., Hirsch F.R., Garrido P., Khan H., Baggi A., Mascaux C., Halmos B., Ceresoli G.L., Fidler M.J., Scotti V., Métivier A.C., Falchero L., Felip E., Genova C., Mazieres J., Tapan U., Brahmer J., Bria E., Puri S., Popat S., Reckamp K.L., Morgillo F., Nadal E., Mazzoni F., Agustoni F., Bar J., Grosso F., Avrillon V., Patel J.D., Gomes F., Ibrahim E., Trama A., Bettini A.C., Barlesi F., Dingemans A.M., Wakelee H., Peters S., Horn L., Garassino M.C., Torri V.
Working group(s)
TERAVOLT study group
ISSN
1556-1380 (Electronic)
ISSN-L
1556-0864
Publication state
Published
Issued date
05/2022
Peer-reviewed
Oui
Volume
17
Number
5
Pages
661-674
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Patients with thoracic malignancies are at increased risk for mortality from coronavirus disease 2019 (COVID-19), and a large number of intertwined prognostic variables have been identified so far.
Capitalizing data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, a global study created with the aim of describing the impact of COVID-19 in patients with thoracic malignancies, we used a clustering approach, a fast-backward step-down selection procedure, and a tree-based model to screen and optimize a broad panel of demographics and clinical COVID-19 and cancer characteristics.
As of April 15, 2021, a total of 1491 consecutive eligible patients from 18 countries were included in the analysis. With a mean observation period of 42 days, 361 events were reported with an all-cause case fatality rate of 24.2%. The clustering procedure screened 73 covariates in 13 clusters. A further multivariable logistic regression for the association between clusters and death was performed, resulting in five clusters significantly associated with the outcome. The fast-backward step-down selection procedure then identified the following seven major determinants of death: Eastern Cooperative Oncology Group-performance status (ECOG-PS) (OR = 2.47, 1.87-3.26), neutrophil count (OR = 2.46, 1.76-3.44), serum procalcitonin (OR = 2.37, 1.64-3.43), development of pneumonia (OR = 1.95, 1.48-2.58), C-reactive protein (OR = 1.90, 1.43-2.51), tumor stage at COVID-19 diagnosis (OR = 1.97, 1.46-2.66), and age (OR = 1.71, 1.29-2.26). The receiver operating characteristic analysis for death of the selected model confirmed its diagnostic ability (area under the receiver operating curve = 0.78, 95% confidence interval: 0.75-0.81). The nomogram was able to classify the COVID-19 mortality in an interval ranging from 8% to 90%, and the tree-based model recognized ECOG-PS, neutrophil count, and c-reactive protein as the major determinants of prognosis.
From 73 variables analyzed, seven major determinants of death have been identified. Poor ECOG-PS was found to have the strongest association with poor outcome from COVID-19. With our analysis, we provide clinicians with a definitive prognostication system to help determine the risk of mortality for patients with thoracic malignancies and COVID-19.
Keywords
C-Reactive Protein, COVID-19, COVID-19 Testing, Humans, Lung Neoplasms/diagnosis, Prognosis, Registries, Retrospective Studies, SARS-CoV-2, Thoracic Neoplasms/diagnosis, Cancer, NSCLC, Registry, TERAVOLT, Thoracic
Pubmed
Web of science
Open Access
Yes
Create date
12/02/2022 15:54
Last modification date
25/01/2024 8:40
Usage data